Trial Profile

Open-label phase 1 study of regorafenib in healthy human subjects

Status: Completed

Phase of Trial: Phase I

Latest Information Update: 21 Feb 2019

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Regorafenib (Primary)
Indications Acute myeloid leukaemia; Adenoid cystic carcinoma; Biliary cancer; Cholangiocarcinoma; Colorectal cancer; Gastrointestinal stromal tumours; Glioblastoma; Liver cancer; Pancreatic cancer; Renal cell carcinoma; Rhabdomyosarcoma; Solid tumours
Focus Adverse reactions; Pharmacokinetics
Acronyms EudraCT2010-019120-31

Most Recent Events

21 Feb 2019 New trial record
01 Jan 2018 This trial is conducted at Charles River Clinical Services Ltd.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com